DE602004017045D1 - Graduierte östrogen-kontrazeptiva - Google Patents

Graduierte östrogen-kontrazeptiva

Info

Publication number
DE602004017045D1
DE602004017045D1 DE602004017045T DE602004017045T DE602004017045D1 DE 602004017045 D1 DE602004017045 D1 DE 602004017045D1 DE 602004017045 T DE602004017045 T DE 602004017045T DE 602004017045 T DE602004017045 T DE 602004017045T DE 602004017045 D1 DE602004017045 D1 DE 602004017045D1
Authority
DE
Germany
Prior art keywords
contrazeptiva
estrogen
graduated
graduated estrogen
contraceptive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004017045T
Other languages
English (en)
Inventor
Roger M Boissonneault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Co LLC
Original Assignee
Warner Chilcott Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Chilcott Co LLC filed Critical Warner Chilcott Co LLC
Publication of DE602004017045D1 publication Critical patent/DE602004017045D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602004017045T 2003-11-14 2004-11-12 Graduierte östrogen-kontrazeptiva Active DE602004017045D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52018203P 2003-11-14 2003-11-14
PCT/US2004/037975 WO2005049142A2 (en) 2003-11-14 2004-11-12 Graduated estrogen contraceptive

Publications (1)

Publication Number Publication Date
DE602004017045D1 true DE602004017045D1 (de) 2008-11-20

Family

ID=34619442

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004017045T Active DE602004017045D1 (de) 2003-11-14 2004-11-12 Graduierte östrogen-kontrazeptiva

Country Status (9)

Country Link
US (2) US8124595B2 (de)
EP (1) EP1689411B1 (de)
JP (1) JP2007511533A (de)
CN (1) CN1878558A (de)
AT (1) ATE410171T1 (de)
CA (1) CA2542854C (de)
DE (1) DE602004017045D1 (de)
IL (1) IL174893A (de)
WO (1) WO2005049142A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2397983T3 (es) * 2004-03-19 2013-03-12 Warner Chilcott Company, Llc Procedimiento anticonceptivo oral multifásico de ciclo prolongado
EP1898953B1 (de) 2005-06-29 2012-12-05 Warner Chilcott Company, LLC Quadraphasisches, kontinuierliches und graduelles östrogen-verhütungsmittel
SG172654A1 (en) 2006-03-02 2011-07-28 Warner Chilcott Co Llc Extended cycle multiphasic oral contraceptive method
WO2009112232A2 (en) * 2008-03-10 2009-09-17 Vladimir Hanes New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
TW200942242A (en) * 2008-03-10 2009-10-16 Rolf Schurmann New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
BR112012026115B1 (pt) 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2021260511A1 (en) 2020-06-25 2021-12-30 Millicent Pharma Limited Multiphasic contraceptive and/or hormone replacement therapy
CA3234836A1 (en) 2021-09-07 2023-03-16 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292315A (en) * 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4921843A (en) 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4962098A (en) * 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
DE4313926A1 (de) 1993-04-28 1994-11-03 Jenapharm Gmbh Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
US5888543A (en) 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
ES2397983T3 (es) * 2004-03-19 2013-03-12 Warner Chilcott Company, Llc Procedimiento anticonceptivo oral multifásico de ciclo prolongado
US7704984B2 (en) * 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
EP1898953B1 (de) * 2005-06-29 2012-12-05 Warner Chilcott Company, LLC Quadraphasisches, kontinuierliches und graduelles östrogen-verhütungsmittel
SG172654A1 (en) * 2006-03-02 2011-07-28 Warner Chilcott Co Llc Extended cycle multiphasic oral contraceptive method

Also Published As

Publication number Publication date
CN1878558A (zh) 2006-12-13
WO2005049142A3 (en) 2005-09-29
EP1689411A2 (de) 2006-08-16
US9132137B2 (en) 2015-09-15
US20110059928A1 (en) 2011-03-10
WO2005049142A2 (en) 2005-06-02
ATE410171T1 (de) 2008-10-15
JP2007511533A (ja) 2007-05-10
US20050107351A1 (en) 2005-05-19
CA2542854C (en) 2012-04-17
IL174893A0 (en) 2009-02-11
IL174893A (en) 2011-11-30
US8124595B2 (en) 2012-02-28
CA2542854A1 (en) 2005-06-02
EP1689411B1 (de) 2008-10-08

Similar Documents

Publication Publication Date Title
IL174893A0 (en) Graduated estrogen contraceptive
SG166107A1 (en) Quadraphasic continuous graduated estrogen contraceptive
IL172959A0 (en) Methods for contraception using estrogen and progestin
TW200603813A (en) Cyclic progestin regimens and kits
NO20025588D0 (no) Inhibitorer for 11-beta-hydroxy steroid dehydrogenase type 1
TR200001460T2 (tr) Çok düşük estrojen dozları kullanılarak menopoz sonrası kadınların tedavisine yönelik metodlar
BRPI0505524A (pt) método passìvel de utilização com um poço subterráneo, sistema passìvel de utilização com um poço subterráneo, e ferramenta passìvel de utilização com um poço subterráneo
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
AU2001251019A1 (en) Method for simulation of enhanced fracture detection in sedimentary basins
IL146904A0 (en) Gypsum compositions and related methods
DK1623711T3 (da) Eksternt plaster indeholdende östrogen og/eller progestogen
MX2007004120A (es) Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente.
AU2002360481A1 (en) Global equation solver and optimizer
FR2849440B1 (fr) Accelerateur de prise liquide pour composition comprenant du ciment portland.
AU2003301129A1 (en) Steroid compositions for intraocular use
IS8008A (is) Efnablanda sem felur í sér samsetningu arómatasahemils, prógestíns og estrógens og notkun hennar til meðhöndlunar legslímuvillu
TW200505896A (en) Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
AR042652A1 (es) Bromhidrato de escitalopram y un metodo para su preparacion
RS90504A (en) C-17 spirolactonization and 6,7 oxidation of steroids
FR2819395B1 (fr) Implant dentaire transitoire de preparation d'une alveole
EP1628660A4 (de) Verfahren und zusammensetzungen zur modulierung der cortisol-serumspiegel
AU2002360565A1 (en) Compositions and methods for normalizing assays
DE602004018921D1 (de) D dienogest
ATE303397T1 (de) 9-alpha-substituierte estratriene als selektiv wirksame estrogene
NO20014444L (no) Topisk appliserbare bioadhesive preparater samt fremgangsmåter for anvendelse og fremstilling derav

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WARNER CHILCOTT COMPANY, LLC, FAJARDO, P.R., US